Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Cystic FibrosisOsteoporosisBone Diseases, Metabolic
Interventions
DRUG

Alendronate

70 mg 1x weekly for 12 months

DRUG

Placebo

70 mg 1 x weekly for 12 months

Trial Locations (6)

T2N 4N1

Dr. Harvey Rabin - Health Sciences Centre, Calgary

Unknown

McMaster University, Hamilton

N6A 4G5

London Health Sciences Centre, London

H2W 1T7

Centre de Recherche - CHUM, Montreal

H2X 2P4

Montreal Chest Institute, Montreal

G1V 4G2

CHUL Hospital, Sainte-Foy

Sponsors
All Listed Sponsors
collaborator

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

collaborator

London Health Sciences Centre

OTHER

collaborator

University of Calgary

OTHER

collaborator

McGill University

OTHER

collaborator

Laval University

OTHER

collaborator

Merck Frosst Canada Ltd.

INDUSTRY

lead

McMaster University

OTHER